Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
National. November 17, 2022: Apollo, Asia’s foremost integrated healthcare services provider today announced the launch of an Antimicrobial Stewardship Programme (Apollo ASP) at a national level. The program will sensitize care providers on Antimicrobial resistance AMR, an issue leading to a public health problem and is today one of humanity’s top ten global public health threats.
Dr Prathap C. Reddy, Chairman, Apollo said, “Antimicrobial Stewardship Programme (Apollo ASP) will be the largest program of its kind in the country to promote the rational use of antibiotics to combat the rising burden of antimicrobial resistance (AMR), also known as drug resistance in the community. The program will sensitize care providers on AMR, an issue leading to a public health problem and is today one of humanity’s top ten global public health threats. Through the Apollo Antimicrobial Stewardship Programme, we aim to optimize the use of antibiotics, turn the tide on AMR, and ensure continued effective treatment of infections for future generations.”
According to Dr Sangita Reddy, Joint Managing Director, Apollo, “The Apollo Antimicrobial Stewardship Programme or Apollo ASP is being launched across the group to improve antimicrobial use and patient outcomes. Apollo ASP will also support the Government of India’s National action plan on the containment of Antimicrobial Resistance (NAP-AMR) and ICMR’s AMR surveillance and research network (AMRSN) to control AMR by empowering doctors to use antibiotics judiciously. Our recent data of over 300 thousand bacterial isolates since 2019 across 20 different locations in India shows a considerable increase in community-acquired Antimicrobial Resistance which warrants immediate measures to stop
this emerging trend. Integrating these insights into clinical decision-making would foster a culture of rational antibiotic use and save lives.”
Dr K Hariprasad, President of Apollo Hospitals said, “Since the discovery of penicillin in 1928, antibiotics have significantly improved global health. They have been a cornerstone of modern medicine, including cancer chemotherapy and advanced surgical procedures. But decades of overuse and misuse of antibiotics have accelerated the emergence and spread of resistant microbes. Today, drug resistance is one of the top ten global public health threats faced by humanity and can have a major impact on modern healthcare. Regular audits and benchmarking of best practices, surveillance and monitoring of metrics for antibiotic consumption and the patient outcome will form an integral part of Apollo ASP”.
Dr Anupam Sibal, Group Medical Director, Apollo said, “The cost of AMR to national economies and their health systems is significant as it results in prolonged hospital stays and the need for more intensive care. Challenges in India to combat the huge burden of antimicrobial resistance (AMR) are manifold considering a sustained annual rise of 5-10% resistance to broad-spectrum antimicrobials. The first steps have already been taken with the formation of a National Advisory Committee to drive consensus on the way forward and roll out of modules for training”.
Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi, and parasites mutate over time and are no longer affected by medicines against them. This makes treating infections caused by them harder to treat and increases the risk of disease spread, severe illness and death. Apollo ASP will implement evidence-based interventions overseen by a multidisciplinary collaborative Antimicrobial Stewardship Programme Committee”.
Infections caused by drug-resistant organisms lead to prolonged duration of hospitalization and increased mortality, causing a huge financial burden to the affected persons, and healthcare systems, and hindering the goals of sustainable development. Antibiotic resistance has led to the emergence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, the bacteria that is responsible for tuberculosis. Antibiotic-resistant strains have emerged among both Gram-positive and Gram-negative bacteria that cause commonly seen infections such as Staphylococcus aureus, Enterococcus species, Pseudomonas aeruginosa, Acinetobacter species, Escherichia coli, Klebsiella pneumonia, and Neisseria gonorrhoeae”.
The program will be backed by a digital backbone that will ensure efficiency, and accuracy and allow an analysis of data for decision-making. The ASP will be integrated with Apollo’s electronic medical records platform – Medmantra to facilitate automated alerts. Education and training of doctors, pharmacists and other healthcare staff will include comprehensive case-based modules.
Apollo revolutionized healthcare when Dr Prathap Reddy opened his first hospital in Chennai in 1983. Today Apollo is the world’s largest vertically integrated healthcare platform with over 10,000 beds across 71 hospitals, 5000 pharmacies, over 400 clinics and diagnostic centres, and 150 telemedicine centres. It is the world’s leading cardiac centre with over 160,000 surgeries and the world’s largest private cancer care provider. Apollo continues to invest in research to bring cutting-edge technologies, equipment and treatment protocols to ensure our patients have the best available care in the world. Our 100,000+ employees are dedicated to bringing you the best care on earth and leaving the world better than we found it.
For further details, log onto: www.apollohospitals.com
Follow us on Twitter: @HospitalsApollo